⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
accessnewswire.com
LEXX
LLY
NVO
PFE
Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
NVO
LLY
Form Health Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
businesswire.com
LLY
NVO
NOVUS Continues Leadership Expansion with Krithika Rosenthal as Managing Director, Strategy & Integrated Outcomes
prnewswire.com
NVO
DG
KHC
CHD
UPS
EBAY
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Trim RX GLP-1 Weight Loss Medication Claims Evaluated: Investigating the TrimRX Treatment Options
globenewswire.com
LLY
NVO
The Galien Foundation Honors 2026 Modi Prix Galien India Award Recipients
prnewswire.com
NVO
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
prnewswire.com
NVO
LLY
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
prnewswire.com
NVO
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
globenewswire.com
NVO